Prothena Co. PLC (NASDAQ:PRTA) Receives $10.00 Consensus Price Target from Brokerages

Shares of Prothena Co. PLC (NASDAQ:PRTA) have received an average recommendation of “Hold” from the six ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.00.

Several equities research analysts have recently weighed in on PRTA shares. Zacks Investment Research raised shares of Prothena from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Wednesday, June 19th. BidaskClub downgraded shares of Prothena from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 15th. ValuEngine raised shares of Prothena from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Barclays reaffirmed a “sell” rating and issued a $9.00 price target on shares of Prothena in a research note on Friday, May 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research note on Thursday, May 16th.

PRTA stock opened at $6.89 on Monday. Prothena has a 52 week low of $6.83 and a 52 week high of $15.91. The firm has a market capitalization of $300.82 million, a P/E ratio of -1.91 and a beta of 2.26. The company has a quick ratio of 14.95, a current ratio of 14.94 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $9.18 and a two-hundred day simple moving average of $10.77.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. Prothena had a negative net margin of 10,435.79% and a negative return on equity of 27.59%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.22 million. As a group, analysts anticipate that Prothena will post -1.97 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can purchased a new position in Prothena in the 2nd quarter worth about $36,000. Meeder Asset Management Inc. purchased a new position in Prothena in the 2nd quarter worth about $37,000. Quantamental Technologies LLC increased its stake in Prothena by 142.9% in the 1st quarter. Quantamental Technologies LLC now owns 4,129 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,429 shares during the period. SG Americas Securities LLC purchased a new position in Prothena in the 1st quarter worth about $114,000. Finally, Prudential Financial Inc. purchased a new position in Prothena in the 2nd quarter worth about $109,000. 99.69% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

See Also: What is Green Investing?

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.